

## Resin Glycosides. XVIII.<sup>1)</sup> Determination by Mosher's Method of the Absolute Configurations of Mono- and Dihydroxyfatty Acids Originated from Resin Glycosides

Masateru ONO, Fumiko YAMADA, Naoki NODA, Toshio KAWASAKI and Kazumoto MIYAHARA\*

Faculty of Pharmaceutical Sciences, Setsunan University, 45-1, Nagaotoge-cho, Hirakata, Osaka 573-01, Japan.

Received November 18, 1992

**The absolute configurations of four hydroxyfatty acids, jalapinic acid, convolvulinic acid, ipurolic acid and 3,11-dihydroxyhexadecanoic acid, obtained by acid hydrolysis of various resin glycosides, have been determined to be 11*S*, 11*S*, 3*S*, 11*S*, and 3*S*, 11*S*, respectively, by Mosher's method. The *R*-configuration of jalapinic acid previously defined by Horeau's method was therefore revised to *S*.**

**Keywords** absolute configuration; hydroxyfatty acid; Mosher's method; (11*S*)-jalapinic acid; (11*S*)-convolvulinic acid; (3*S*, 11*S*)-ipurolic acid

The so-called resin glycosides, which are characteristic components of Convolvulaceae plants, contain a variety of hydroxyfatty acids such as jalapinic acid (11-hydroxyhexadecanoic acid), convolvulinic acid (11-hydroxytetradecanoic acid), ipurolic acid (3,11-dihydroxytetradecanoic acid), and 3,11-dihydroxyhexadecanoic acid, *etc.*<sup>2)</sup> as the aglycones of their glycosidic acid moieties.

In the course of our structural study on the resin glycosides of *Ipomoea orizabensis*, the absolute configuration at 11-C of (+)-jalapinic acid (**1**) has been taken as *R*<sup>3)</sup> according to Horeau's method.<sup>4)</sup> But, the result was suspected to be possibly erroneous, because the specific optical rotation of the enantiomeric mixture of (+)- and (–)-2-phenylbutyric acids obtained from the excess amounts of their anhydride used in esterification was very small ( $[\alpha]_D + 0.46^\circ$ ).

We have now conducted a reexamination by the more reliable Mosher's method<sup>5)</sup> based on another principle, and, as reported preliminarily, it has been concluded that the configuration should be not *R*, but *S*.<sup>6)</sup> At the same time, Kitagawa *et al.* have synthesized *S*- and *R*-jalapinic acids *via* Sharpless asymmetric epoxidation and also determined the configuration of (+)-jalapinic acid ( $[\alpha]_D + 0.5^\circ$ ), which they obtained from the resin glycosides of the tuber of *Merremia mammosa*, to be *S* by direct comparison.<sup>7)</sup>

Further, convolvulinic acid (**2**), ipurolic acid (**3**) and 3,11-dihydroxyhexadecanoic acid (**4**) have been examined by Mosher's method, and they were assigned the configurations 11*S*, 3*S*, 11*S* and 3*S*, 11*S*, respectively. This paper deals with the details of the determinations.

As the first step, in order to establish whether Mosher's method is applicable to a hydroxyfatty acid such as **1**, having one chiral center located in the middle of a straight and rather long methylene chain, methyl (+)-jalapinolate (**5**) was oxidized followed by reduction to give the racemate (**6**), and the <sup>1</sup>H-NMR spectrum (400 MHz, in CDCl<sub>3</sub>) of its (*R*)-(+)-2-methoxy-2-trifluoromethylphenylacetate (MTPA ester) (**7**) was taken. The spectrum showed, along with a sharp triple triplet due to 11-H ( $\delta$  5.088) and a triplet due to 2-H<sub>2</sub> ( $\delta$  2.298), a pair of triplets assignable to the terminal 16-H<sub>3</sub> at  $\delta$  0.840 and 0.876. However, none of 12–15-H<sub>2</sub> could be assigned. Therefore, commercial 2*S*-pentanol (**8**),  $[\alpha]_D + 13.2^\circ$  (neat), 2*S*-hexanol (**9**),  $[\alpha]_D$

+ 10.6° (neat) and 2*S*-heptanol (**10**),  $[\alpha]_D + 9.5^\circ$  (neat),<sup>8)</sup> were converted into the corresponding (–)- and (+)-MTPA esters (**11**, **12**; **13**, **14**; **15**, **16**) and their <sup>1</sup>H-NMR spectra were recorded. All the pairs of compounds showed in their spectra a pair of triplets due to the terminal H<sub>3</sub>, and the magnitudes of the chemical shift differences ( $\Delta\delta$ ), [ $\delta$ (–)-MTPA ester –  $\delta$ (+)-MTPA ester], all having a positive value, decreased with increasing number of methylene groups from the chiral centers (Fig. 1). It is considered that the chemical shift difference at the terminal methyl signals of **7** arises substantially from the difference of configurations at 11-C and that Mosher's method is applicable to determine the configuration of a chiral center by use of the signals of the terminal methyl group, which is separated by as much as four methylene groups from the asymmetric carbon.

The <sup>1</sup>H-NMR spectra of the (–)- and (+)-MTPA esters (**17** and **18**) of methyl (+)-jalapinolate (**5**),  $[\alpha]_D + 1.0^\circ$ , exhibited the 16-H<sub>3</sub> signal at  $\delta$  0.840 and 0.878, respectively. The  $\Delta\delta$  value, –0.038 ppm, indicates the configuration at 11-C of **1** to be *S* (Fig. 1). All the specimens of methyl jalapinolate (**5**), obtained from glycosidic acids of the ether-soluble resin glycosides (jalapins), such as orizabins,<sup>3)</sup> muricatin,<sup>9)</sup> merremosides,<sup>10)</sup> mammosides,<sup>10)</sup> operculins,<sup>11)</sup> scammonins<sup>12)</sup> and simonins,<sup>13)</sup> also showed + $[\alpha]_D$  values and were considered to have 11*S* configuration.

The (–)- and (+)-MTPA esters (**19** and **20**) of methyl convolvulinolate (**21**),  $[\alpha]_D + 1.0^\circ$ , obtained either from quamoclines of the seeds of *Quamoclit pennata*<sup>14)</sup> or rhamnoconvolvulin<sup>15)</sup> of Mexican Jalap, exhibited 14-H<sub>3</sub> signals at  $\delta$  0.850 and 0.918, respectively. The  $\Delta\delta$  value, –0.068 ppm, shows **2** to have 11*S*-configuration.

Ipurolic acid (**3**), the common aglycone of pharbitic acids C and D<sup>16)</sup> from pharbitin, an ether-insoluble resin glycoside (convolvulin) of Pharbitidis Semen, is 3,11-dihydroxytetradecanoic acid, that is, 3-hydroxyconvolvulinic acid.

Application of Mosher's method (or its modification using a lanthanide shift reagent) to several 3-hydroxy-carboxylic acids has been reported,<sup>17)</sup> and we attempted to apply the method to **3**. As a model experiment, commercial methyl 3*S*-hydroxybutyrate (**22**),<sup>8)</sup>  $[\alpha]_D + 18.0^\circ$  (neat), was esterified to afford diastereomeric (–)- and




Fig. 1. Values of  $^1\text{H-NMR}$  Chemical Shift Difference (ppm) [ $\Delta\delta$ :  $\delta(-)\text{-MTPA} - \delta(+)\text{-MTPA}$  Ester ( $\times 10^{-3}$ )] for MTPA Esters (400 MHz)




Fig. 2.  $^1\text{H-NMR}$  Spectra of **26** and **27** (in  $\text{CDCl}_3$ , 400 MHz)

(+)-MTPA esters (**23** and **24**). Their  $^1\text{H-NMR}$  spectra showed signals due to the  $4\text{-H}_3$ ,  $2\text{-H}_a$ ,  $2\text{-H}_b$  and ester methyl protons, and the  $\Delta\delta$  values in regard to the respective proton(s) were  $-0.086$ ,  $+0.035$ ,  $+0.044$  and  $+0.082$  ppm. These data are consistent with those predicted for  $3S$ -configuration of **22**. Therefore, the configuration at  $3\text{-C}$  of **3** could be determined by use of the 2-methylene and ester methyl signals.

Ipurolic acid methyl ester (**25**),  $[\alpha]_D + 1.2^\circ$ , was completely acylated by (–)- and (+)-MTPACl to give (–)- and (+)-MTPA diesters (**26** and **27**). Comparison of the  $^1\text{H-NMR}$  spectrum of **26** with that of **27** showed, similarly to the case of **19** and **20**, as well as **23** and **24**, the  $\Delta\delta$  values  $-0.066$ ,  $+0.026$ ,  $+0.044$  and  $+0.068$  ppm in regard to  $14\text{-H}_3$ ,  $2\text{-H}_a$ ,  $2\text{-H}_b$  and ester methyl proton signals, respectively (Fig. 2), suggesting that the configurations at  $3\text{-C}$  and  $11\text{-C}$  of **3** are both  $S$ . However, the possibility can not necessarily be excluded that the  $\Delta\delta$  values might be affected by interaction between the two MTPA residues at  $3\text{-C}$  and  $11\text{-C}$  in **26** and **27**. This possibility was ruled out as follows.

Methyl 11-hydroxytetradec-2-enoate (**28**), which was prepared from crude pharbitic acid by successive dehydra-

tion with  $\text{AcONa-Ac}_2\text{O}$ , and alkaline and acidic hydrolyses according to Okabe *et al.*,<sup>18)</sup> was hydrogenated to afford methyl 11-hydroxytetradecanoate (**21**). Its  $[\alpha]_D$  value, melting point and  $^{13}\text{C-NMR}$  spectrum were identical with those of methyl convolvulinolate (**21**). Compound **25** was partially oxidized to give methyl 3-hydroxy-11-oxotetradecanoate (**29**), and the  $^1\text{H-NMR}$  spectra of its (–)- and (+)-MTPA esters (**30** and **31**) showed  $\Delta\delta$  values of  $+0.031$ ,  $+0.051$  and  $+0.074$  ppm for the  $2\text{-H}_a$ ,  $2\text{-H}_b$  and ester methyl proton signals, respectively, in parallel with those between **23** and **24**.

Thus, the configurations at both  $3\text{-C}$  and  $11\text{-C}$  of **3** are properly regarded as  $S$ .

The methyl ester (**32**) of 3,11-dihydroxyhexadecanoic acid (**4**), the aglycone of pharbitic acid **B**,<sup>16)</sup> was converted into the (–)- and (+)-MTPA esters (**33** and **34**). Comparison of their  $^1\text{H-NMR}$  spectra revealed the  $\Delta\delta$  values of  $-0.035$ ,  $+0.027$ ,  $+0.045$  and  $+0.065$  ppm for  $16\text{-H}_3$ ,  $2\text{-H}_a$ ,  $2\text{-H}_b$  and ester methyl proton signals, respectively. By analogy with the case of **3**, **4** is also considered to have the  $3S,11S$ -configurations.

The  $^1\text{H-NMR}$  spectra of the MTPA esters of **5**, **21**, **25** and **32** exhibited no signals due to their counterpart

diastereomers, and hence compounds **1**, **2**, **3** and **4** obtained from the resin glycosides were considered to be optically pure.

Mosher's method was thus found to be useful for determination of the absolute configuration and optical purity of a minute amount of hydroxyfatty acid, whose specific rotation is small (less than 2°).

#### Experimental

<sup>1</sup>H-NMR spectra were recorded on a JEOL JNM GSX-400 spectrometer (400 MHz) at 25 °C using tetramethylsilane as an internal reference. Optical rotations were determined on a JASCO DIP-140 polarimeter at 16–22 °C.

**Preparation of 6** A mixture of 1% CrO<sub>3</sub>–pyridine (3 ml) was added to a solution of **5** (300 mg) in pyridine (1 ml), and the mixture was left to stand at room temperature overnight. The reaction mixture was poured into ice water (20 ml) and extracted with ether (20 ml × 3). The extractive was purified by silica gel chromatography (*n*-hexane–AcOEt, 1:1) to give methyl 11-oxohexadecanoate (**35**) (224 mg), colorless needles (petroleum ether), mp 38–39 °C, electron impact (EI)-MS *m/z*: 284 [M]<sup>+</sup>. NaBH<sub>4</sub> (30 mg) was added in portions to a solution of **35** (163 mg) in MeOH (2.5 ml) for 5 min under stirring. The mixture was worked up in the usual manner to furnish **6** (145 mg), colorless needles (petroleum ether), mp 44–45 °C; field desorption (FD)-MS *m/z*: 287 [M+H]<sup>+</sup>, 269 [M+H–H<sub>2</sub>O]<sup>+</sup>, 215 [M–CH<sub>3</sub>(CH<sub>2</sub>)<sub>4</sub>]<sup>+</sup>, 186, 135, 101, [CH<sub>3</sub>(CH<sub>2</sub>)<sub>4</sub>–CH(OH)]<sup>+</sup>.

**Preparation of 21'** A solution of crude pharbitic acid (3.0 g) and AcONa (6.0 g) in Ac<sub>2</sub>O (60 ml) was heated at 95 °C for 5 h and poured into ice-water to afford yellowish precipitates (3.6 g). They were refluxed with 3.5% KOH–EtOH (60 ml), and the mixture was neutralized with 2N HCl then evaporated *in vacuo*. The residue was hydrolyzed with 2N HCl (50 ml) at 90 °C for 2 h. The mixture was extracted with ether (50 ml × 3) and the ether layer was washed with H<sub>2</sub>O (30 ml × 2) then evaporated. The residue was methylated with ethereal diazomethane and the product was subjected successively to silica gel chromatography (*n*-hexane: AcOEt = 5:1), preparative HPLC (Kusano CIG prepacked Si, 2.2 cm i.d. × 10 cm, *n*-hexane: AcOEt = 5:1) and vacuum distillation to give **28** (115 mg), a colorless oil, bp 166–167 °C (4 mmHg). <sup>1</sup>H-NMR (in CDCl<sub>3</sub>, 400 MHz) δ: 0.928 (3H, t, *J* = 7.0 Hz, 14-H<sub>3</sub>), 2.196 (2H, ddt, *J* = 1.2, 7.0, 7.0 Hz, 4-H<sub>2</sub>), 3.597 (1H, m, 11-H), 3.726 (3H, s, OCH<sub>3</sub>), 5.818 (1H, dt, *J* = 15.6, 1.2 Hz, 2-H), 6.972 (1H, dt, *J* = 15.6, 7.0 Hz, 3-H). <sup>13</sup>C-NMR (in CDCl<sub>3</sub>) δ: 14.1 (14-C), 18.8, 15.6, 28.0, 29.1, 29.4, 29.6, 32.2, 37.5, 39.7, 51.4 (OCH<sub>3</sub>), 71.7 (11-C), 120.8 (2-C), 149.8 (3-C), 167.2 (1-C).

A suspension of **28** (115 mg) and 10% palladium on charcoal (50 mg) in 1,4-dioxane (5 ml) was stirred under a hydrogen atmosphere for 5 h. The catalyst was filtered off and the filtrate was concentrated *in vacuo* to give **21'** (77 mg), colorless needles (petroleum ether), mp 34 °C, [*α*]<sub>D</sub> +0.9° (*c* = 4.6, CHCl<sub>3</sub>). This product was identical with an authentic sample of methyl convulvinolate<sup>13</sup> as judged from a comparison of their <sup>13</sup>C-NMR spectra.

**Preparation of 29** A mixture of CrO<sub>3</sub>–pyridine (8%, 10 ml) was added to a solution of **25** (100 mg) in CH<sub>2</sub>Cl<sub>2</sub>–pyridine (1:1, 6 ml). The mixture was stirred at room temperature for 4.5 h, diluted with water (150 ml), then extracted with ether (50 ml × 5). The ether layer was dried over MgSO<sub>4</sub> and concentrated *in vacuo* to give a residue. It was subjected to silica gel column chromatography (*n*-hexane: AcOEt = 4:1 → 3:1 → 2:1 → AcOEt) to give **29** (46 mg), colorless needles (*n*-hexane–AcOEt), mp 42–43 °C. <sup>1</sup>H-NMR (in CDCl<sub>3</sub>) δ: 0.910 (3H, t, *J* = 7.3 Hz, 14-H<sub>3</sub>), 1.595 (2H, tq, *J* = 7.3, 7.3 Hz, 13-H<sub>2</sub>), 2.372 (2H, t, *J* = 7.3 Hz, 12-H<sub>2</sub>), 2.379 (2H, t, *J* = 7.3 Hz, 10-H<sub>2</sub>), 2.409 (1H, dd, *J* = 9.2, 16.5 Hz, 2-H<sub>a</sub>), 2.515 (1H, dd, *J* = 3.1, 16.5 Hz, 2-H<sub>b</sub>), 2.874 (1H, d, *J* = 4.0 Hz, 3-OH), 3.717 (3H, s, OCH<sub>3</sub>), 3.997 (1H, m, 3-H). <sup>1</sup>H-NMR (in pyridine-*d*<sub>5</sub>) δ: 0.853 (3H, t, *J* = 7.3 Hz, 14-H<sub>3</sub>), 2.314 (2H, t, *J* = 7.0 Hz, 12-H<sub>2</sub> or 10-H<sub>2</sub>), 2.328 (2H, t, *J* = 7.0 Hz, 10-H<sub>2</sub> or 12-H<sub>2</sub>), 2.700 (1H, dd, *J* = 4.5, 15.0 Hz, 2-H<sub>a</sub>), 2.766 (1H, dd, *J* = 8.0, 15.0 Hz, 2-H<sub>b</sub>), 3.647 (3H, s, OCH<sub>3</sub>), 4.438 (1H, m, 3-H). <sup>13</sup>C-NMR (in pyridine-*d*<sub>5</sub>) δ: 13.9 (14-C), 17.5, 24.1, 26.1, 29.5, 29.8, 38.1, 42.7, 43.5, 44.5, 51.3 (OCH<sub>3</sub>), 68.1 (3-C), 172.8 (1-C), 210.3 (11-C). EI-MS *m/z*: 272 [M]<sup>+</sup>, 254 [M–H<sub>2</sub>O]<sup>+</sup>, 187 [(CH<sub>2</sub>)<sub>7</sub>CH(OH)CH<sub>2</sub>COOH]<sup>+</sup>, 71 [C<sub>3</sub>H<sub>7</sub>CO]<sup>+</sup> and methyl 3,11-dioxotetradecanoate (36 mg), colorless needles (*n*-hexane–AcOEt), mp 44–45 °C. <sup>1</sup>H-NMR (in CDCl<sub>3</sub>) δ: 0.909 (3H, t, *J* = 7.3 Hz, 14-H<sub>3</sub>), 2.368 (3H, t, *J* = 7.3 Hz, 12-H<sub>2</sub> or 10-H<sub>2</sub>), 2.376 (3H, t, *J* = 7.6 Hz, 10-H<sub>2</sub> or 12-H<sub>2</sub>), 2.526 (2H, t, *J* = 7.3 Hz, 4-H<sub>2</sub>), 3.441 (2H, s, 2-H<sub>2</sub>), 3.734 (3H, s, OCH<sub>3</sub>). <sup>13</sup>C-NMR (in CDCl<sub>3</sub>) δ: 13.8 (14-C), 17.3, 23.3, 23.7, 28.8, 29.0, 29.1, 42.7, 43.0, 44.7, 49.0, 52.3 (OCH<sub>3</sub>), 167.7 (1-C), 202.8 (3-C), 211.5 (11-C). EI-MS *m/z*: 270 [M]<sup>+</sup>, 185

[(CH<sub>2</sub>)<sub>7</sub>COCH<sub>2</sub>COOH]<sup>+</sup>, 71 [C<sub>3</sub>H<sub>7</sub>CO]<sup>+</sup>.

**Preparation of (–)- and (+)-MTPA Esters, 7, 17, 18, 19, 20, 26, 27, 30, 31, 33 and 34** Freshly prepared (–)- or (+)-MTPA chloride (10–120 mg) was added to a solution of a starting hydroxy compound (1–45 mg) in pyridine (2 ml) and CCl<sub>4</sub> (5 drops), and the mixture was left to stand at room temperature overnight. The solvent was removed under an N<sub>2</sub> stream to give a residue. The residue was purified by chromatography over silica gel (benzene: AcOEt = 10:1 → 8:1 → 5:1 → AcOEt) to furnish the corresponding MTPA ester in a yield of 50–98%.

**7**: 47 mg, a colorless oil. <sup>1</sup>H-NMR (in CDCl<sub>3</sub>) δ: 0.840, 0.876 (each 3/2H, t, *J* = 7.0 Hz, 16-H<sub>3</sub>), 2.298 (2H, t, *J* = 7.6 Hz, 2-H<sub>2</sub>), 3.557 (3H, q, *J* = 1.2 Hz, OCH<sub>3</sub>), 3.658, 3.660 (each 3/2H, s, COOCH<sub>3</sub>), 5.088 (1H, tt, *J* = 5.5, 7.0 Hz, 11-H).

**17**: 31 mg, a colorless oil. <sup>1</sup>H-NMR (in CDCl<sub>3</sub>) δ: 0.840 (3H, t, *J* = 6.9 Hz, 16-H<sub>3</sub>), 2.298 (2H, t, *J* = 7.5 Hz, 2-H<sub>2</sub>), 3.556 (3H, q, *J* = 1.2 Hz, OCH<sub>3</sub>), 3.663 (3H, s, COOCH<sub>3</sub>), 5.083 (1H, tt, *J* = 5.5, 6.7 Hz, 11-H).

**18**: 28 mg, a colorless oil. <sup>1</sup>H-NMR (in CDCl<sub>3</sub>) δ: 0.878 (3H, t, *J* = 6.9 Hz, 16-H<sub>3</sub>), 2.299 (2H, t, *J* = 7.5 Hz, 2-H<sub>2</sub>), 3.557 (3H, q, *J* = 1.2 Hz, OCH<sub>3</sub>), 3.664 (3H, s, COOCH<sub>3</sub>), 5.083 (1H, tt, *J* = 5.5, 6.7 Hz, 11-H).

**19**: 23 mg, a colorless oil. <sup>1</sup>H-NMR (in CDCl<sub>3</sub>) δ: 0.850 (3H, t, *J* = 7.3 Hz, 14-H<sub>3</sub>), 2.298 (2H, t, *J* = 7.5 Hz, 2-H<sub>2</sub>), 3.552 (3H, q, *J* = 1.2 Hz, OCH<sub>3</sub>), 3.662 (3H, s, COOCH<sub>3</sub>), 5.098 (1H, tt, *J* = 5.3, 7.0 Hz, 11-H).

**20**: 23 mg, a colorless oil. <sup>1</sup>H-NMR (in CDCl<sub>3</sub>) δ: 0.918 (3H, t, *J* = 7.3 Hz, 14-H<sub>3</sub>), 2.299 (2H, t, *J* = 7.6 Hz, 2-H<sub>2</sub>), 3.560 (3H, q, *J* = 1.2 Hz, OCH<sub>3</sub>), 3.664 (3H, s, COOCH<sub>3</sub>), 5.096 (1H, tt, *J* = 5.5, 7.0 Hz, 11-H).

**26**: 110 mg, a colorless oil. <sup>1</sup>H-NMR (in CDCl<sub>3</sub>) δ: 0.853 (3H, t, *J* = 7.3 Hz, 14-H<sub>3</sub>), 2.600 (1H, dd, *J* = 4.6, 15.9 Hz, 2-H<sub>a</sub>), 2.694 (1H, dd, *J* = 7.9, 15.9 Hz, 2-H<sub>b</sub>), 3.539 (3H, br s, OCH<sub>3</sub>), 3.548 (3H, q, br s, OCH<sub>3</sub>), 3.656 (3H, s, COOCH<sub>3</sub>), 5.094 (1H, ddt, *J* = 5.2, 6.5, 6.5 Hz, 11-H), 5.467 (1H, ddt, *J* = 5.0, 6.8, 6.8 Hz, 3-H).

**27**: 70 mg, a colorless oil. <sup>1</sup>H-NMR (in CDCl<sub>3</sub>) δ: 0.919 (3H, t, *J* = 7.3 Hz, 14-H<sub>3</sub>), 2.574 (1H, dd, *J* = 4.9, 15.9 Hz, 2-H<sub>a</sub>), 2.650 (1H, dd, *J* = 7.9, 15.9 Hz, 2-H<sub>b</sub>), 3.527 (3H, q, *J* = 1.2 Hz, OCH<sub>3</sub>), 3.563 (3H, q, *J* = 1.2 Hz, OCH<sub>3</sub>), 3.588 (3H, s, COOCH<sub>3</sub>), 5.095 (1H, tt, *J* = 5.7, 7.0 Hz, 11-H), 5.474 (1H, ddt, *J* = 4.9, 7.9, 6.0 Hz, 3-H).

**30**: 1 mg, a colorless oil. <sup>1</sup>H-NMR (in CDCl<sub>3</sub>) δ: 0.913 (3H, t, *J* = 7.5 Hz, 14-H<sub>3</sub>), 2.369 (2H, t, *J* = 7.4 Hz, 12-H<sub>2</sub>), 2.373 (2H, t, *J* = 7.3 Hz, 10-H<sub>2</sub>), 2.604 (1H, dd, *J* = 4.6, 16.2 Hz, 2-H<sub>a</sub>), 2.699 (1H, dd, *J* = 8.1, 16.2 Hz, 2-H<sub>b</sub>), 3.543 (3H, q, *J* = 1.2 Hz, OCH<sub>3</sub>), 3.663 (3H, s, COOCH<sub>3</sub>), 5.473 (1H, ddt, *J* = 4.6, 8.1, 5.5 Hz, 3-H).

**31**: 1 mg, a colorless oil. <sup>1</sup>H-NMR (in CDCl<sub>3</sub>) δ: 0.911 (3H, t, *J* = 7.5 Hz, 14-H<sub>3</sub>), 2.372 (2H, t, *J* = 7.4 Hz, 12-H<sub>2</sub>), 2.376 (2H, t, *J* = 7.3 Hz, 10-H<sub>2</sub>), 2.573 (1H, dd, *J* = 4.9, 16.2 Hz, 2-H<sub>a</sub>), 2.648 (1H, dd, *J* = 7.9, 16.2 Hz, 2-H<sub>b</sub>), 3.527 (3H, d, *J* = 0.7 Hz, OCH<sub>3</sub>), 3.589 (3H, s, COOCH<sub>3</sub>), 5.473 (1H, ddt, *J* = 4.9, 7.9, 6.0 Hz, 3-H).

**33**: 45 mg, a colorless oil. <sup>1</sup>H-NMR (in CDCl<sub>3</sub>) δ: 0.842 (3H, t, *J* = 6.8 Hz, 16-H<sub>3</sub>), 2.600 (1H, dd, *J* = 4.8, 16.0 Hz, 2-H<sub>a</sub>), 2.695 (1H, dd, *J* = 8.0, 16.0 Hz, 2-H<sub>b</sub>), 3.541 (3H, q, *J* = 0.9 Hz, OCH<sub>3</sub>), 3.555 (3H, q, *J* = 0.9 Hz, OCH<sub>3</sub>), 3.655 (3H, s, COOCH<sub>3</sub>), 5.082 (1H, tt, *J* = 5.5, 7.0 Hz, 11-H), 5.469 (1H, ddt, *J* = 4.8, 8.0, 6.3 Hz, 3-H).

**34**: 31 mg, a colorless oil. <sup>1</sup>H-NMR (in CDCl<sub>3</sub>) δ: 0.877 (3H, t, *J* = 7.0 Hz, 16-H<sub>3</sub>), 2.573 (1H, dd, *J* = 4.9, 15.9 Hz, 2-H<sub>a</sub>), 2.650 (1H, dd, *J* = 8.0, 15.9 Hz, 2-H<sub>b</sub>), 3.527 (3H, q, *J* = 1.2 Hz, OCH<sub>3</sub>), 3.558 (3H, q, *J* = 1.2 Hz, OCH<sub>3</sub>), 3.590 (3H, s, COOCH<sub>3</sub>), 5.081 (1H, tt, *J* = 5.5, 7.0 Hz, 11-H), 5.470 (1H, ddt, *J* = 4.9, 8.0, 6.0 Hz, 3-H).

**Preparation of (–)- and (+)-MTPA Esters, 11, 12, 13, 14, 15, 16, 23 and 24** Freshly prepared (–)- or (+)-MTPA chloride (45 mg) was added to a solution of starting material (10 mg) in pyridine (0.5 ml) and CCl<sub>4</sub> (10 drops), and the mixture was left to stand at room temperature overnight. It was then diluted with H<sub>2</sub>O (5 ml) and extracted with ether (5 ml × 3). The organic layer was washed with 0.2N HCl (10 ml), 0.3% aqueous Na<sub>2</sub>CO<sub>3</sub> (10 ml) and H<sub>2</sub>O (10 ml × 2), successively. The ether layer was dried over MgSO<sub>4</sub> and concentrated under reduced pressure to afford a colorless oil (yield 67–86%).

**11**: 24 mg, a colorless oil. <sup>1</sup>H-NMR (in CDCl<sub>3</sub>) δ: 0.921 (3H, t, *J* = 7.3 Hz, 5-H<sub>3</sub>), 1.251 (3H, d, *J* = 6.1 Hz, 1-H<sub>3</sub>), 1.527 (1H, m, 3-H<sub>a</sub>), 1.690 (1H, m, 3-H<sub>b</sub>), 3.549 (3H, q, *J* = 1.2 Hz, OCH<sub>3</sub>), 5.153 (1H, ddq, *J* = 5.1, 7.5, 6.1 Hz, 2-H).

**12**: 22 mg, a colorless oil. <sup>1</sup>H-NMR (in CDCl<sub>3</sub>) δ: 0.858 (3H, t, *J* = 7.3 Hz, 5-H<sub>3</sub>), 1.332 (3H, d, *J* = 6.3 Hz, 1-H<sub>3</sub>), 1.479 (1H, m, 3-H<sub>a</sub>), 1.632 (1H, m, 3-H<sub>b</sub>), 3.562 (3H, q, *J* = 1.2 Hz, OCH<sub>3</sub>), 5.167 (1H, ddq, *J* = 5.0, 7.6, 6.3 Hz, 2-H).

**13**: 21 mg, a colorless oil. <sup>1</sup>H-NMR (in CDCl<sub>3</sub>) δ: 0.888 (3H, t, *J* = 7.0 Hz, 6-H<sub>3</sub>), 1.252 (3H, d, *J* = 6.1 Hz, 1-H<sub>3</sub>), 1.558 (1H, m, 3-H<sub>a</sub>), 1.688 (1H, m, 3-H<sub>b</sub>), 3.548 (3H, q, *J* = 1.2 Hz, OCH<sub>3</sub>), 5.139 (1H, ddq, *J* = 5.1, 7.0, 6.1 Hz,

2-H).

**14:** 22 mg, a colorless oil.  $^1\text{H-NMR}$  (in  $\text{CDCl}_3$ )  $\delta$ : 0.831 (3H, t,  $J=7.0$  Hz, 6- $\text{H}_3$ ), 1.330 (3H, d,  $J=6.3$  Hz, 1- $\text{H}_3$ ), 1.511 (1H, m, 3- $\text{H}_a$ ), 1.623 (1H, m, 3- $\text{H}_b$ ), 3.567 (3H, q,  $J=1.2$  Hz,  $\text{OCH}_3$ ), 5.153 (1H, ddq,  $J=5.1, 7.0, 6.3$  Hz, 2-H).

**15:** 19 mg, a colorless oil.  $^1\text{H-NMR}$  (in  $\text{CDCl}_3$ )  $\delta$ : 0.878 (3H, t,  $J=6.9$  Hz, 7- $\text{H}_3$ ), 1.251 (3H, d,  $J=6.1$  Hz, 1- $\text{H}_3$ ), 1.546 (1H, m, 3- $\text{H}_a$ ), 1.676 (1H, m, 3- $\text{H}_b$ ), 3.547 (3H, q,  $J=1.2$  Hz,  $\text{OCH}_3$ ), 5.140 (1H, ddq,  $J=5.0, 7.0, 6.1$  Hz, 2-H).

**16:** 20 mg, a colorless oil.  $^1\text{H-NMR}$  (in  $\text{CDCl}_3$ )  $\delta$ : 0.839 (3H, t,  $J=7.0$  Hz, 7- $\text{H}_3$ ), 1.330 (3H, d,  $J=6.3$  Hz, 1- $\text{H}_3$ ), 1.503 (1H, m, 3- $\text{H}_a$ ), 1.620 (1H, m, 3- $\text{H}_b$ ), 3.569 (3H, q,  $J=1.2$  Hz,  $\text{OCH}_3$ ), 5.157 (1H, ddq,  $J=5.0, 7.3, 6.3$  Hz, 2-H).

**23:** 21 mg, a colorless oil.  $^1\text{H-NMR}$  (in  $\text{CDCl}_3$ )  $\delta$ : 1.336 (3H, d,  $J=6.4$  Hz, 4- $\text{H}_3$ ), 2.573 (1H, dd,  $J=4.7, 16.2$  Hz, 2- $\text{H}_a$ ), 2.727 (1H, dd,  $J=8.5, 16.2$  Hz, 2- $\text{H}_b$ ), 3.526 (3H, q,  $J=1.2$  Hz,  $\text{OCH}_3$ ), 3.663 (3H, s,  $\text{COOCH}_3$ ), 5.543 (1H, ddq,  $J=4.7, 8.5, 6.4$  Hz, 3-H).

**24:** 20 mg, a colorless oil.  $^1\text{H-NMR}$  (in  $\text{CDCl}_3$ )  $\delta$ : 1.422 (3H, d,  $J=6.4$  Hz, 4- $\text{H}_3$ ), 2.538 (1H, dd,  $J=5.1, 16.0$  Hz, 2- $\text{H}_a$ ), 2.683 (1H, dd,  $J=8.2, 16.0$  Hz, 2- $\text{H}_b$ ), 3.535 (3H, q,  $J=1.2$  Hz,  $\text{OCH}_3$ ), 3.581 (3H, s,  $\text{COOCH}_3$ ), 5.550 (1H, ddq,  $J=5.1, 8.2, 6.4$  Hz, 3-H).

**Acknowledgment** We wish to thank Dr. Masatoshi Nishi of this University for the measurements of NMR spectra.

#### References and Notes

- 1) Part XVII: M. Ono, T. Ueguchi, T. Kawasaki and K. Miyahara, *Yakugaku Zasshi*, **112**, 866 (1992).
- 2) H. Wagner, "Medicine and Natural Sciences, Chemistry in Botanical Classification," ed. by G. Bendz and J. Santesson, Academic Press, New York and London, 1974, p. 235.
- 3) N. Noda, M. Ono, K. Miyahara, T. Kawasaki and M. Okabe, *Tetrahedron*, **43**, 3889 (1987).
- 4) A. Horeau, *Tetrahedron Lett.*, **1961**, 506; *idem, ibid.*, **1962**, 965; J. P. Guette and A. Horeau, *ibid.*, **1965**, 3040; A. Horeau and H. B. Kagan, *Tetrahedron*, **20**, 2431 (1964).
- 5) J. A. Dale and H. S. Mosher, *J. Am. Chem. Soc.*, **95**, 512 (1973).
- 6) M. Ono, K. Kubo, T. Kawasaki and K. Miyahara, *Chem. Pharm. Bull.*, **37**, 241 (1989).
- 7) H. Shibuya, K. Kawashima, N. I. Baek, N. Narita, M. Yoshikawa and I. Kitagawa, *Chem. Pharm. Bull.*, **37**, 260 (1989).
- 8) These compounds were purchased from Wako Pure Chemical Industries, Ltd.
- 9) N. Noda, H. Kobayashi, K. Miyahara and T. Kawasaki, *Chem. Pharm. Bull.*, **36**, 920 (1988); N. Noda, M. Nishi, K. Miyahara and T. Kawasaki, *ibid.*, **36**, 1707 (1988).
- 10) I. Kitagawa, H. Shibuya, Y. Yokokawa, N. I. Baek, K. Ohashi, M. Yoshikawa, A. Nitta and H. Wiriadinata, *Chem. Pharm. Bull.*, **36**, 1618 (1988); I. Kitagawa, N. I. Baek, K. Ohashi, M. Sakagami, M. Yoshikawa and H. Shibuya, *ibid.*, **37**, 1131 (1989).
- 11) M. Ono, M. Nishi, T. Kawasaki and K. Miyahara, *Chem. Pharm. Bull.*, **38**, 2986 (1990); M. Ono, T. Kawasaki and K. Miyahara, *ibid.*, **39**, 2534 (1991); M. Ono, K. Fujimoto, M. Kawata, T. Fukunaga, T. Kawasaki and K. Miyahara, *ibid.*, **40**, 1400 (1992).
- 12) N. Noda, H. Kogetsu, T. Kawasaki and K. Miyahara, *Phytochemistry*, **29**, 3565 (1990); H. Kogetsu, N. Noda, T. Kawasaki and K. Miyahara, *ibid.*, **30**, 957 (1991); N. Noda, H. Kogetsu, T. Kawasaki and K. Miyahara, *ibid.*, **31**, 2761 (1992).
- 13) N. Noda, S. Yoda, T. Kawasaki and K. Miyahara, *Chem. Pharm. Bull.*, **40**, 3163 (1992).
- 14) M. Ono, K. Kuwabata, T. Kawasaki and K. Miyahara, *Chem. Pharm. Bull.*, **40**, 2674 (1992).
- 15) C. Mannich and P. Schumann, *Arch. Pharm. Dtsch. Pharm. Ges.*, **276**, 221 (1938); M. Ono, F. Yamada, M. Nishi, N. Noda, K. Miyahara and T. Kawasaki, Abstracts of Papers, 105th Annual Meeting of the Pharmaceutical Society of Japan, Hiroshima, April 1988, p. 349.
- 16) H. Okabe and T. Kawasaki, *Tetrahedron Lett.*, **1970**, 3123; M. Ono, N. Noda, T. Kawasaki and K. Miyahara, *Chem. Pharm. Bull.*, **38**, 1892 (1990).
- 17) H. Akita, A. Furuichi, H. Koshiji, K. Horikoshi and T. Oishi, *Chem. Pharm. Bull.*, **31**, 4376 (1983); F. Yasuda and S. Yamaguchi, *Tetrahedron Lett.*, **21**, 2827 (1980).
- 18) H. Okabe, N. Koshito, K. Tanaka and T. Kawasaki, *Chem. Pharm. Bull.*, **19**, 2394 (1971).